Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 5 Startups & Unicorns companies in Peripheral neuropathy
by Most Market Reports in the world in 2019

The Peripheral neuropathy top 5 is Discovery PatSnap’ annual ranking of the top 5 Most Market Reports Peripheral neuropathy Startups & Unicorns in the world. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2019, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
A disease affecting peripheral nerves.

Key Players

Fast-growings

Startups & Unicorns

New Entrants

Ranking Year:

2022

2021

2020

2019

Region:

Global

Ranking:

Most Patent Filings

Highest Patent Value

Most Market Reports

Most News Heat

#
Company Name
Region
Tech Topics
Total
1
Achelios Therapeutics, Inc.
North Carolina, United States
Academic medicine,Health care,Pharmacy and Therapeutics,
...[+2]
market report: 3
2
PeriphaGen
Pennsylvania, United States
Gene delivery,Medical equipment,Neuron,
...[+2]
market report: 1
3
Novaremed AG
Basel-Stadt, Switzerland
Molecule,Medicine,Drug,
...[+2]
market report: 1
4
DermaXon LLC
United States
Chemotherapy-induced peripheral neuropathy,Apomorphine,Safinamide,
...[+2]
market report: 1
5
Metys Pharmaceuticals AG
Basel-Stadt, Switzerland
Chemotherapy-induced peripheral neuropathy,Dimiracetam,Medical equipment,
...[+2]
market report: 1

Who we serve

R&D Decision MakersNew Product Innovation LeaderTechnology Research AnalystsBusiness Development Professionals

Why Discovery

Technology Intelligence Data FoundationAI-powered Competitive Intelligence RadarTechnology Classification and Company Innovation Indicators

Social media

Try Discovery

Free Trial
PatSnap group products
Browse By:ABCDEFGHIJKLMNOPQRSTUVWXYZ#All topics,List of companies,Sitemap
© 2023 PatSnap. All rights reserved.Legal | Privacy policy Modern Slavery Act Transparency Statement
Page generation time: Jul 22 2025
For better visiting experience, please use PC device.X